Company Description
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases.
Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis.
It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301.
The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021.
Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Brian Strem |
Contact Details
Address: 332 Encinitas Boulevard, Suite 102 Encinitas, California 92024 United States | |
| Phone | 858 224 9600 |
| Website | kiorapharma.com |
Stock Details
| Ticker Symbol | KPRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001372514 |
| CUSIP Number | 49721T101 |
| ISIN Number | US49721T5074 |
| Employer ID | 98-0443284 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Brian M. Strem Ph.D. | President, Chief Executive Officer and Director |
| Melissa Tosca CPA | Chief Financial Officer |
| Dr. Stefan Sperl Ph.D. | Executive Vice President of CMC and Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 28, 2026 | 424B3 | Prospectus |
| May 22, 2026 | EFFECT | Notice of Effectiveness |
| May 18, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 8, 2026 | 8-K | Current Report |
| May 8, 2026 | 10-Q | Quarterly Report |
| May 1, 2026 | ARS | Filing |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |